At Wintermute Biomedical, our sole focus is to develop innovative solutions where current medicines are failing.
We are a global biopharmaceutical company with offices in Melbourne, Australia and California, USA. Founded in 2012, we have discovered a next generation antibiotic, which we think will have a significant impact on the lives of many patients across the globe. We won’t rest until this new antibiotic is available to the many patients who desperately need it.
Meet Tom and Wes. Frustrated by a lack of new antibiotics to address the impending AMR crisis, they were determined to discover a truly novel, next generation antibiotic. Through restless innovation and breakthrough science, they discovered a new compound that shows no signs of succumbing to AMR any time soon. Tom and Wes founded Wintermute Biomedical to take this antibiotic from the lab to the hands of millions of patients around the globe.
Wintermute Biomedical is driven by an experienced team of healthcare innovators, infectious disease experts and entrepreneurs.
Geoff is an engineer, entrepreneur and company executive, with extensive experience in the healthcare sector. He has successfully co-founded and led a number of high-growth, high-tech companies.
Tom is a Wintermute co-founder and inventor, with over 20 years experience in scientific research. He specializes in neuroscience and medical microbiology, with a particular focus on multidrug-resistant bacteria.
Priscilla is a healthcare innovator and experienced leader of research teams. She specializes in the research, development and translation of technologies to the health sector, both in corporate and start-up settings.
Matt has spent over 25 years in the development and commercialization of healthcare technology. He specialises in market development strategies, working with multinational healthcare companies and start-ups alike.
Wes is a Wintermute co-founder and a keen enthusiast for developing new and innovative solutions to address global health challenges, such as antimicrobial resistance.
Wintermute Biomedical is surrounded by world leading experts in microbiology, antimicrobial resistance, infectious disease and medicine.
Andrew is a practising cardiologist, with significant experience in research and bringing new medical innovations to market. He holds a number of leadership positions, with special research interests in cardiology, primary prevention, and infection control.
There are a number of people who have been critical to the establishment and progress of Wintermute Biomedical. We would like to thank our investors, subject matter experts, and extended friends of the Wintermute family. A special thanks to:
Paul Cohn
Tony Peacock
Ros Peacock
Patrick Dennis
Matt Godden
Peter Tregear
John Kennedy
Andrew Ajani
Emma Guymer
Robert Goodman
Paul Dowie
Kristie Raymond
Brad Bond
David Hughes
Bill Goodman
Marion Goodman
Doug Birer
